98 related articles for article (PubMed ID: 8993373)
1. Both epidermal growth factor-like domains of the merozoite surface protein-1 from Plasmodium yoelii are required for protection from malaria.
Calvo PA; Daly TM; Long CA
Ann N Y Acad Sci; 1996 Oct; 797():260-2. PubMed ID: 8993373
[No Abstract] [Full Text] [Related]
2. Passive immunization with antibodies against three distinct epitopes on Plasmodium yoelii merozoite surface protein 1 suppresses parasitemia.
Spencer Valero LM; Ogun SA; Fleck SL; Ling IT; Scott-Finnigan TJ; Blackman MJ; Holder AA
Infect Immun; 1998 Aug; 66(8):3925-30. PubMed ID: 9673281
[TBL] [Abstract][Full Text] [Related]
3. The combined epidermal growth factor-like modules of Plasmodium yoelii Merozoite Surface Protein-1 are required for a protective immune response to the parasite.
Ling IT; Ogun SA; Holder AA
Parasite Immunol; 1995 Aug; 17(8):425-33. PubMed ID: 7501423
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of immunogenicity of an oral Salmonella vaccine expressing recombinant Plasmodium berghei merozoite surface protein-1.
Toebe CS; Clements JD; Cardenas L; Jennings GJ; Wiser MF
Am J Trop Med Hyg; 1997 Feb; 56(2):192-9. PubMed ID: 9080880
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies.
Matsumoto S; Yukitake H; Kanbara H; Yamada T
J Exp Med; 1998 Sep; 188(5):845-54. PubMed ID: 9730886
[TBL] [Abstract][Full Text] [Related]
6. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge.
Rénia L; Ling IT; Marussig M; Miltgen F; Holder AA; Mazier D
Infect Immun; 1997 Nov; 65(11):4419-23. PubMed ID: 9353014
[TBL] [Abstract][Full Text] [Related]
7. Synthetic peptides based on conserved Plasmodium falciparum antigens are immunogenic and protective against Plasmodium yoelii malaria.
Chauhan VS; Chatterjee S; Johar PK
Parasite Immunol; 1993 Apr; 15(4):239-42. PubMed ID: 7685076
[TBL] [Abstract][Full Text] [Related]
8. Definition of T cell epitopes within the 19 kDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) and their role in immunity to malaria.
Tian JH; Good MF; Hirunpetcharat C; Kumar S; Ling IT; Jackson D; Cooper J; Lukszo J; Coligan J; Ahlers J; Saul A; Berzofsky JA; Holder AA; Miller LH; Kaslow DC
Parasite Immunol; 1998 Jun; 20(6):263-78. PubMed ID: 9651928
[TBL] [Abstract][Full Text] [Related]
9. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge.
Wang L; Goschnick MW; Coppel RL
Infect Immun; 2004 Oct; 72(10):6172-5. PubMed ID: 15385527
[TBL] [Abstract][Full Text] [Related]
10. Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection.
Daly TM; Long CA
Infect Immun; 1996 Jul; 64(7):2602-8. PubMed ID: 8698485
[TBL] [Abstract][Full Text] [Related]
11. Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii.
Tian JH; Kumar S; Kaslow DC; Miller LH
Infect Immun; 1997 Aug; 65(8):3032-6. PubMed ID: 9234750
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoelii.
Kedzierski L; Black CG; Stowers AW; Goschnick MW; Kaslow DC; Coppel RL
Vaccine; 2001 Sep; 19(32):4661-8. PubMed ID: 11535314
[TBL] [Abstract][Full Text] [Related]
13. Merozoite surface protein-1 epitopes recognized by antibodies that inhibit Plasmodium falciparum merozoite dispersal.
Lyon JA; Carter JM; Thomas AW; Chulay JD
Mol Biochem Parasitol; 1997 Dec; 90(1):223-34. PubMed ID: 9497045
[TBL] [Abstract][Full Text] [Related]
14. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria.
Daly TM; Long CA
J Immunol; 1995 Jul; 155(1):236-43. PubMed ID: 7602100
[TBL] [Abstract][Full Text] [Related]
15. Protection of mice against Plasmodium yoelii sporozoite challenge with P. yoelii merozoite surface protein 1 DNA vaccines.
Becker SI; Wang R; Hedstrom RC; Aguiar JC; Jones TR; Hoffman SL; Gardner MJ
Infect Immun; 1998 Jul; 66(7):3457-61. PubMed ID: 9632624
[TBL] [Abstract][Full Text] [Related]
16. Protection of Aotus monkeys after immunization with recombinant antigens of Plasmodium falciparum.
Enders B; Hundt E; Knapp B
Mem Inst Oswaldo Cruz; 1992; 87 Suppl 3():413-22. PubMed ID: 1343721
[TBL] [Abstract][Full Text] [Related]
17. Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii.
Kedzierski L; Black CG; Goschnick MW; Stowers AW; Coppel RL
Infect Immun; 2002 Dec; 70(12):6606-13. PubMed ID: 12438332
[TBL] [Abstract][Full Text] [Related]
18. A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice.
Daly TM; Long CA
Infect Immun; 1993 Jun; 61(6):2462-7. PubMed ID: 8363656
[TBL] [Abstract][Full Text] [Related]
19. Immunity to erythrocytic stages of malarial parasites.
Long CA; Daly TM; Kima P; Srivastava I
Am J Trop Med Hyg; 1994; 50(4 Suppl):27-32. PubMed ID: 7909653
[TBL] [Abstract][Full Text] [Related]
20. Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection.
Petritus PM; Burns JM
J Immunol; 2008 Jan; 180(1):444-53. PubMed ID: 18097046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
